Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

Gastric cancer is not a top‐10 malignancy in the United States but represents one of the
most common causes of cancer death worldwide. Biological differences between tumors …

Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

There exist differences in the epidemiological characteristics, clinicopathological features,
tumor biological characteristics, treatment patterns, and drug selections between gastric …

Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …

Opinion statement Despite a decreasing incidence in the USA, gastric cancer is highly
prevalent worldwide. Furthermore, gastric cancer remains highly lethal with median survival …

Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …

Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐
overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there …